Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/11440
Title: Central venous access device-associated complication costs in paediatrics: a systematic review
Authors: Comber, E. R.;Ullman, A. J. ;Hall, S. ;Takashima, M.;Nguyen, L.;Keogh, S.;Byrnes, J.
Issue Date: 2025
Source: J Hosp Infect, 2025 (169) p.59-67
Pages: 59-67
Journal Title: J Hosp Infect
Abstract: Paediatric patients who are critically unwell typically require a central venous access device (CVAD) to streamline medical procedures and minimise risks associated with repeated venipuncture. However, infectious and non-infectious complications are common, with considerable clinical and cost sequelae. This review aimed to identify the mean cost of CVAD-associated complications in paediatric hospital-based care and explore cost variation based on clinical and health services characteristics. This systematic review used the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. EMBASE, CINAHL, PubMed, Web of Science, Cochrane Library (CENTRAL) and EconLit databases were searched for studies published in English between January 2012 and January 2025, which calculated CVAD-associated complication costs in paediatrics. Of the 3932 studies identified in database searching, 22 studies were included. CVAD-associated complication costs ranged widely based on complication type, hospital setting and country and showed high heterogeneity, likely due to the types of costs included in cost estimates. Methods for calculating these costs were only reported in one of these studies. CVAD-associated complications, particularly infectious complications, incur substantial costs ranging from $3684.32 to $378,288.81 (2024 USD).
DOI: 10.1016/j.jhin.2025.11.009
Appears in Sites:Children's Health Queensland Publications
Queensland Health Publications

Show full item record

Page view(s)

88
checked on Oct 8, 2026

Google ScholarTM

Check

Altmetric


Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.